GENE ONLINE|News &
Opinion
Blog

2021-11-07| Special

Scientists Engineer RNA Switches for Targeted Delivery of Gene Therapy and RNA Therapeutics

by Sahana Shankar
Share To
The biggest challenge of gene therapy is to ensure that it reaches the target cells and is inhibited from acting on unintended cells. This specificity can enable systemic delivery of the drug without risks from off-target effects. Designing such specific molecular switches has received much attention from bioengineers and synthetic biologists.

In a breakthrough study, scientists from MIT and Harvard University engineered a novel RNA-based gating system that can trigger the expression of transgenes and subsequent production of therapeutics. The study, published in Nature Biotechnology, reports an efficient design for future gene therapy.

By reading tissue-specific transcription profiles to identify target cells, the authors devised a specific homing strategy called eToeholds to prevent off-target effects. eToehold is an RNA module that regulates the translation of the reporter gene based on its interaction with specific trigger RNAs (tgRNAs) present in only specific cells.

GO Prime with only $1.49 now

LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top